Introduction {#s1}
============

Neural tube defects (NTDs) are a group of severe congenital malformations with an average worldwide birth prevalence of 1 in 500 [@pone.0041689-vanderPut1], occurring due to incomplete closure of the neural tube between days 22 and 26 (somite stage 10--12) during embryo development [@pone.0041689-Koch1]. These birth defects can cause lifelong disability or death.

Although the cause of NTDs is still poorly understood, accumulated evidence has suggested that genetic and/or environmental factors may contribute to NTD aetiology. Among these factors, maternal nutritional status is a key determinant of pregnancy outcome, and attention has been focused on folic acid, a water-soluble B vitamin that acts as a cofactor in one-carbon transfer reactions and plays a central role in DNA methylation, synthesis, and repair [@pone.0041689-Hosseini1], [@pone.0041689-Zeisel1]. It has been shown that the occurrence and recurrence risk of NTDs is reduced by 50--70% with folic acid supplementation during the periconceptional period [@pone.0041689-Speer1]. However, the underlying mechanisms by which folic acid protects against NTDs are still unknown. In addition, it is not known why some women who take folic acid supplements during the periconceptional period still have offspring with NTDs [@pone.0041689-Marini1]. Therefore, candidate genes that encode enzymes involved in folate metabolism or receptors involved in folate transport have been analysed.

![The studies inclusion and exclusion procedures.](pone.0041689.g001){#pone-0041689-g001}

The enzyme *MTHFR* plays a key role in the folate metabolism pathway and regulates the intracellular folate pool for synthesis and methylation of DNA [@pone.0041689-Das1], [@pone.0041689-Ueland1]. The *MTHFR* gene is located at chromosome 1p36.3 and is 2.2 kb in length with a total of 11 exons [@pone.0041689-Goyette1]. Several single nucleotide polymorphisms in the *MTHFR* gene have been characterised, with the *C677T* polymorphism as the most important and best studied [@pone.0041689-Sameer1]. The C-to-T transition at nucleotide 677 in exon 4 is a point mutation that converts a cytosine (C) to a thymine (T), resulting in an amino acid substitution of alanine to valine [@pone.0041689-Sharp1], which can be detected functionally because it decreases the thermal stability of this enzyme during in vitro incubation of cell extracts at 46°C for 5 min [@pone.0041689-Kang1]. This mutation reduces enzyme activity, decreases concentration of folate in the serum, plasma, and red blood cells and increases total plasma homocysteine concentrations [@pone.0041689-vanderPut2], which explains a substantial part of the observed elevated plasma homocysteine levels in mothers with NTD-affected offspring.

10.1371/journal.pone.0041689.t001

###### Characteristics of the association studies on maternal MTHFRC677T polymorphism and the risk of Neural tube defects (NTDs).

![](pone.0041689.t001){#pone-0041689-t001-1}

  ID                             first author                             year   Source of control   Region    Ethnicity   total   Case genetypes CC/CT/TT   Control genetypes CC/CT/TT                    HWE
  ---- ----------------------------------------------------------------- ------ ------------------- --------- ----------- ------- ------------------------- ---------------------------- ----------------------------------------
  1                    Arbour L [@pone.0041689-Arbour1]                   2002         mixed         Canada    Caucasian    175           32/31/11                    52/38/11                            0.319
  2                   Candito M [@pone.0041689-Candito1]                  2008          HB           France    Caucasian    138           25/40/12                    26/29/6                             0.610
  3                    Ceyhan ST [@pone.0041689-Ceyhan1]                  2008          HB           Turkey    Caucasian    64             9/14/6                     20/12/3                             0.544
  4               Christensen B [@pone.0041689-Christensen1]              1999          HB           Canada    Caucasian    152           24/27/11                    44/36/10                            0.526
  5                     Dalal A [@pone.0041689-Dalal1]                    2007          PB            India    Caucasian    143            56/21/6                    45/12/3                             0.095
  6                       Deb R [@pone.0041689-Deb1]                      2011          PB            India    Caucasian    333            80/25/6                    149/64/9                            0.524
  7                     Félix TM [@pone.0041689-Felix1]                   2004          HB           Brazil    Caucasian    85             19/15/7                    16/22/6                             0.718
  8                   Godbole K [@pone.0041689-Godbole1]                  2011          HB            India    Caucasian    989           238/62/5                   521/158/5                            0.059
  9                   Houcher B [@pone.0041689-Houcher1]                  2009          HB           Algeria    African     174           35/42/15                    33/35/14                            0.375
  10                 Lacasana M [@pone.0041689-Lacasana1]                 2012          HB           Mexico      Mixed      189           11/45/42                    20/49/22                            0.460
  11                       Li K [@pone.0041689-Li1]                       2000          HB            China      Asian      51             1/17/9                      5/16/3                             0.093
  12                   Lucock M [@pone.0041689-Lucock1]                   2000          PB             UK      Caucasian    50              8/9/2                     11/17/3                             0.330
  13    Martínez de Villarreal LE [@pone.0041689-MartinezdeVillarreal1]   2001          PB           Mexico      Mixed      69            11/12/15                    12/16/3                             0.479
  14                   Molloy AM [@pone.0041689-Molloy1]                  1998          HB           Ireland   Caucasian    343           34/35/13                   119/121/21                           0.200
  15                    Munoz JB [@pone.0041689-Munoz1]                   2007          HB           Mexico      Mixed      230           14/54/50                    25/57/30                            0.833
  16                  Naushad SM [@pone.0041689-Naushad1]                 2010          PB            India    Caucasian    130            33/11/6                    64/16/0                             0.320
  17           Parle-McDermott A [@pone.0041689-ParleMcDermott1]          2003          HB           Ireland   Caucasian    529          102/138/34                  126/103/26                           0.469
  18                    Perez AB [@pone.0041689-Perez1]                   2003          HB           Brazil      Mixed      257            67/55/9                    70/54/2             0.019[\*](#nt101){ref-type="table-fn"}
  19                   Relton CL [@pone.0041689-Relton1]                  2004          HB             UK      Caucasian    698           86/78/22                   191/254/67                           0.222
  20                   Relton CL [@pone.0041689-Relton2]                  2004          HB             UK      Caucasian    251           31/36/15                    66/88/15                            0.058
  21                    Shang Y [@pone.0041689-Shang1]                    2008          HB            China      Asian      118            14/20/4                    25/38/17                            0.718
  22                  Shields DC [@pone.0041689-Shields1]                 1999          HB           Ireland   Caucasian    460           80/108/30                  114/108/20                           0.426
  23                   Ubbink JB [@pone.0041689-Ubbink1]                  1999          PB           Africa     African     107            42/11/0                    43/11/0                             0.405
  24                     Wang F [@pone.0041689-Wang1]                     2008          HB            China      Asian      198           14/50/35                    34/48/17                            0.990
  25                       Yu J [@pone.0041689-Yu1]                       2000          PB            China      Asian      66             2/25/15                     5/16/3                             0.093

P\<0.05.

In the past decade, studies have investigated the association between the *C677T MTHFR* polymorphism and NTD susceptibility. However, these studies have failed to yield a consistent conclusion. Therefore, we performed a meta-analysis of all studies published until January 2012 to explore this inconsistency and to investigate the association between the maternal *MTHFR C677T* polymorphism and risk of NTDs.

![Forest plot of NTD risk associated with the maternal *MTHFR C677T* polymorphism (TT+CT vs. CC) in overall populations.](pone.0041689.g002){#pone-0041689-g002}

Materials and Methods {#s2}
=====================

Study eligibility {#s2a}
-----------------

Potentially relevant reports were selected by searching Embase and PubMed (the last search update was performed on January 10, 2012) using the main search terms "methylene-tetrahydrofolate reductase," "*MTHFR*," and "neural tube defects," "NTD". All studies were published in English or in the Chinese language, and were human studies only. The related reference articles were searched to identify other relevant publications. Unpublished data and further information were also obtained from the authors.

10.1371/journal.pone.0041689.t002

###### Summary of comparisons for maternal MTHFRC677T polymorphism and risk of Neural tube defects (NTDs).
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  Contrast              Variables     Comparisons      OR            95% CI             P        P[\*](#nt102){ref-type="table-fn"} ~heterogeneity~
  ------------------- -------------- ------------- ----------- ------------------ ------------- ----------------------------------------------------
  TT vs CC               Overall          24        **2.022**   **1.508--2.712**   **\<0.001**                         0.006
                       Study design                                                             
                            PB             6        **2.756**   **1.528--4.970**    **0.001**                          0.112
                            HB            17        **1.951**   **1.404--2.713**   **\<0.001**                         0.006
                          Mixed            1          1.625       0.632--4.179        0.314                              \-
                        Ethnicity                                                               
                          Asian            4          3.750      0.732--19.217        0.113                            0.003
                        Caucasian         15        **1.596**   **1.271--2.005**   **\<0.001**                         0.280
                         African           1          1.010       0.423--2.411        0.982                              \-
                          Mixed            4        **3.595**   **2.139--6.042**   **\<0.001**                         0.888
  CT vs CC               Overall          25          1.154       0.982--1.357        0.083                            0.053
                       Study design                                                             
                            PB             7          0.991       0.717--1.370        0.955                            0.525
                            HB            17          1.188       0.973--1.451        0.014                            0.017
                          Mixed            1          1.326       0.694--2.532        0.393                              \-
                        Ethnicity                                                               
                          Asian            4        **1.933**   **1.167--3.202**    **0.010**                          0.198
                        Caucasian         15          1.080       0.886--1.316        0.445                            0.039
                         African           2          1.095       0.641--1.872        0.740                            0.864
                          Mixed            4          1.248       0.877--1.775        0.218                            0.566
  CT+TT vs CC            Overall          25        **1.303**   **1.089--1.558**    **0.004**                          0.002
                       Study design                                                             
                            PB             7          1.174       0.867--1.588        0.299                            0.210
                            HB            17        **1.318**   **1.060--1.639**    **0.013**                          0.001
                          Mixed            1          1.393       0.762--2.546        0.282                              \-
                        Ethnicity                                                               
                          Asian            4          2.455       0.886--6.803        0.084                            0.026
                        Caucasian         15          1.186       0.968--1.454        0.100                            0.011
                         African           2          1.075       0.644--1.792        0.783                            0.904
                          Mixed            4        **1.576**   **1.125--2.208**    **0.008**                          0.450
  TT vs CT+CC            Overall          24        **1.716**   **1.448--2.033**   **\<0.001**                         0.134
                       Study design                                                             
                            PB             6        **2.818**   **1.62--4.882**    **\<0.001**                         0.214
                            HB            17        **1.631**   **1.359--1.958**   **\<0.001**                         0.147
                          Mixed            1          1.429       0.583--3.498        0.435                              \-
                        Ethnicity                                                               
                          Asian            4          1.949       0.752--5.056        0.170                            0.033
                        Caucasian         15        **1.524**   **1.227--1.893**   **\<0.001**                         0.632
                         African           1          0.946       0.426--2.102        0.892                              \-
                          Mixed            4        **2.514**   **1.720--3.676**   **\<0.001**                         0.412
  2TT+CT vs 2CC +CT      Overall          25        **1.330**   **1.160--1.525**   **\<0.001**                         0.001
                       Study design                                                             
                            PB             7        **1.462**   **1.006--2.124**    **0.047**                          0.045
                            HB            17        **1.305**   **1.116--1.525**    **0.001**                          0.001
                          Mixed            1          1.320       0.840--2.074        0.228                              \-
                        Ethnicity                                                               
                          Asian            4          1.633       0.908--2.939        0.102                            0.009
                        Caucasian         15        **1.223**   **1.049--1.427**    **0.010**                          0.013
                         African           2          1.029       0.698--1.516        0.886                            0.985
                          Mixed            4        **1.653**   **1.331--2.052**   **\<0.001**                         0.470

: Random-effects model was used when P value for heterogeneity test\<0.10; otherwise, fix-effects model was used.

Validity assessment {#s2b}
-------------------

Potential studies were selected following inclusion criteria: 1) *MTHFR C677T* polymorphism and NTDs; 2) human case-control design; 3) sufficient maternal genotype data for estimating an odds ratio (OR) with a 95% confidence interval (CI); and 4) published in English or Chinese. The criteria for the exclusion of studies are as follows: 1) not related to the *MTHFR C677T* polymorphism and NTDs; 2) not a primary case-control study; 3) no usable or sufficient maternal genotype data reported: and 4) controls are not mothers with at least one healthy birth.

![Begg\'s Funnel plot of NTD risk associated with the maternal *MTHFR C677T* polymorphism (TT vs. CC +CT) in overall populations.\
Each point represents a separate study for the indicated association.](pone.0041689.g003){#pone-0041689-g003}

Data extraction {#s2c}
---------------

Two investigators independently extracted the data from all eligible studies using the selection criteria listed above. Any disagreement was resolved by discussion. We extracted the following information: the first author\'s name, year of publication, the country in which the study was conducted, the ethnicities of the individuals involved, the source of control groups (population-based or hospital-based controls or mixed), the sample size, number of cases and controls with the CC, CT, and TT genotypes.

Data synthesis {#s2d}
--------------

All statistical analyses were performed using the STATA software (version 11). Two-sided *P* values less than 0.05 were considered statistically significant. For the control groups of each study, the observed genotype frequencies of the *MTHFR C677T* polymorphism were assessed for Hardy-Weinberg equilibrium.

The strength of the association between the *MTHFR C677T* polymorphism and NTD risk was evaluated by the odds ratios (ORs) with 95% confidence intervals (CIs). The pooled ORs were calculated for the homozygote comparison (TT versus CC), heterozygote comparison (CT versus CC), dominant model (CT + TT versus CC), recessive model (TT versus CT + CC), and an additive model (2TT + CT versus 2CC + CT). Subgroup analyses were performed based on the source of controls and ethnicity if the data permitted.

The evaluation of the meta-analysis results included a test for heterogeneity, an analysis of the sensitivity, and an examination for bias. The chi-squared test-based Q-statistic was calculated to test the heterogeneity between studies and detect the source of heterogeneity by ethnicity, publication year, control source, and sample size. The model used for the analysis of the pooled ORs depends on the *P* value. If the heterogeneity test result was *P*\<0.1, the pooled ORs were analysed using the random-effects model (the DerSimonian and Laird method) [@pone.0041689-DerSimonian1]; otherwise, the fixed-effects model was used (the Mantel-Haenszel method) [@pone.0041689-Mantel1]. Additionally, sensitivity analyses were performed after sequential removal of each study. Finally, the Begg\'s funnel plot and Egger\'s test were performed to statistically analyse the publication bias [@pone.0041689-Egger1].

Results {#s3}
=======

Study characteristics {#s3a}
---------------------

We included 25 eligible studies [@pone.0041689-Arbour1]--[@pone.0041689-Yu1] in our meta-analysis. The studies contained data on 5999 mothers (2429 case mothers and 3570 control mothers) who had an *MTHFR C677T* polymorphism in the case-control design. The characteristics of all reports on the association between the *MTHFRC677T* polymorphism and NTDs are shown in [Table 1](#pone-0041689-t001){ref-type="table"}. In our meta-analysis, 7 studies were population-based controls, 17 studies were hospital-based controls, 1 did not provide detailed information regarding the source of the controls were mixed; 4 studies included Asian populations, 15 studies were Caucasian population, 2 studies were African population, and 4 studies were mixed population (white and non-white). The genotype distributions in the controls for all studies were consistent with Hardy-Weinberg equilibrium, except for the controls in a study by Perez et al.[@pone.0041689-Perez1]. [Figure 1](#pone-0041689-g001){ref-type="fig"} shows the study selection procedure.

Evidence synthesis {#s3b}
------------------

In our meta-analysis the CC genotype was used as the reference group. The maternal *MTHFRC677T* polymorphism showed pooled odds ratios for homozygote comparison (TT versus CC: OR  = 2.022, 95% CI: 1.508, 2.712, *P*\<0.001), for dominant model comparison (CT+TT versus CC: OR  = 1.303, 95% CI: 1.089, 1.558, *P* = 0.004), for recessive model comparison (TT versus CC+CT: OR  = 1.716, 95% CI: 1.448, 2.033, *P*\<0.001), and for additive model comparison (2TT+CT versus 2CC+CT: OR  = 1.330, 95% CI: 1.160, 1.525, *P*\<0.001). Overall, there was a significant association between the maternal *MTHFR C677T* polymorphism and NTDs. The forest plot is shown in [Figure 2](#pone-0041689-g002){ref-type="fig"}.

Subgroup analysis {#s3c}
-----------------

We also performed subgroup analysis stratified by ethnicity and study design. We found that the variant genotypes were associated with a significantly increased NTD risk in Asian, Caucasian and mixed populations. In heterozygote comparison ( CT versus CC), the pooled odds ratio was 1.933 (95%CI: 1.167, 3.202, *P* = 0.010) for Asian population. The pooled odds ratios were 1.524 (95% CI: 1.227, 1.893, *P*\<0.001), and 2.514 (95% CI: 1.720, 3.676, *P*\<0.001) for Caucasian and mixed populations, respectively, under the recessive model. However, we did not find an association between the *C677T* polymorphism and NTD risk in African groups in any genetic models. The meta-analysis results for the other genetic models are listed in [Table 2](#pone-0041689-t002){ref-type="table"}.

Significantly increased risks were also found in the subgroup analysis stratified by the source of the controls. The pooled odds ratios were 2.756 (95% CI: 1.528, 4.970, *P* = 0.001) in the population-based control subgroups and 1.951 (95% CI: 1.404, 2.713, *P*\<0.001) in the hospital-based control subgroups by homozygote comparison. The meta-analysis results for the other genetic models are listed in [Table 2](#pone-0041689-t002){ref-type="table"}.

Test for heterogeneity {#s3d}
----------------------

There was significant heterogeneity in four genetic models: TT versus CC: *P* ~heterogeneity~  = 0.006; CT versus CC: *P* ~heterogeneity~  = 0.053; CT + TT versus CC: *P* ~heterogeneity~  = 0.002; and 2TT + CT versus 2CC + CT: *P* ~heterogeneity~ \<0.001). Data are listed in [Table 2](#pone-0041689-t002){ref-type="table"}. We assessed the source of heterogeneity by ethnicity, publication year, control source, and sample size. However, we did not observe any sources that contribute to the substantial heterogeneity.

Sensitivity analysis and cumulative meta-analysis {#s3e}
-------------------------------------------------

Sensitivity analyses were conducted to ascertain the primary origin of the heterogeneity. Two independent studies by Relton CL[@pone.0041689-Relton1] and Wang F[@pone.0041689-Wang1] affected the heterogeneity in maternal case-control studies. The heterogeneity was effectively decreased by the exclusion of the two studies: Heterogeneity chi-squared  = 48.33, *P* ~heterogeneity~  = 0.002 and heterogeneity chi-squared  = 29.94, *P* ~heterogeneity~  = 0.120, before and after removal, respectively. Furthermore, no single study qualitatively changed the pooled ORs, suggesting that the results of this meta-analysis were stable. In the cumulative meta-analysis, the pooled ORs tended to be stable, and the associations tended towards significant associations with the accumulation of more data over time.

Publication bias {#s3f}
----------------

Funnel plots were generated to assess publication bias. Egger\'s test was performed to statistically evaluate funnel plot symmetry. The results showed no evidence of publication bias: *P* = 0.034, 95% CI: 0.125, 2.824 ([Figure 3](#pone-0041689-g003){ref-type="fig"}).

Discussion {#s4}
==========

The folate metabolism pathway plays an important role in DNA methylation, DNA synthesis, cell division, and tissue growth, especially in the rapidly developing cells [@pone.0041689-Morrison1]. Thus, a defective folate metabolism could result in an impaired DNA synthesis or DNA methylation involved in the neurulation process. *MTHFR* is a key enzyme in the folate metabolism pathway. Although several single nucleotide polymorphisms (SNPs) in the *MTHFR* gene have been characterised, the *C677T* polymorphism is a widely described mutation. Heterozygotes (CT) for the polymorphism have 65% of the normal enzyme activity and 10% lower red blood cell folate level; patients with the homozygous variant (TT) have only 30% of normal enzyme activity and 18% lower red blood cell folate levels [@pone.0041689-Molloy2], [@pone.0041689-Rozen1]. Additionally, individuals with the TT variant also have lowered plasma folate and vitamin B~12~ levels and increased homocysteine levels [@pone.0041689-Ma1], [@pone.0041689-Ma2]. Overall, due to its potential role in decreasing *MTHFR* activity, causing high plasma homocysteine and low plasma folate levels, it contributes to NTDs [@pone.0041689-vanderPut3]. Despite the potential implication of *MTHFR C677T* in the pathogenesis of NTDs [@pone.0041689-Candito1]--[@pone.0041689-Dalal1], [@pone.0041689-Houcher1]--[@pone.0041689-Li1], [@pone.0041689-MartinezdeVillarreal1]--[@pone.0041689-Perez1], [@pone.0041689-Shang1], [@pone.0041689-Shields1], [@pone.0041689-Wang1], [@pone.0041689-Yu1], the association between the *MTHFR C677T* polymorphism and NTDs remains unclear.

Our meta-analysis, which included 2429 cases and 3570 controls, explored the associations between the maternal *MTHFR* C667T polymorphism and susceptibility to NTDs. Overall, we found that mothers with the homozygous TT genotype showed a significantly increased NTD risk compared with homozygous CC genotype carriers (with pooled odds ratio 2.022; 95% CI: 1.508, 2.712; *P*\<0.001). Our results were consistent with a previous report [@pone.0041689-Botto1]that showed an overall odds ratio of 2.04 (TT versus CC: 95% CI: 1.49, 2.81).

In subgroup analysis stratified by ethnicity, we found that the variant genotypes were associated with a significantly increased NTD risk in Asian, Caucasian and mixed populations. However, we did not found this association in African groups in any genetic model, possibly due to the limited studies and a small sample size. Moreover, the pooled odds ratios of mixed populations were higher than those of Caucasian populations and the overall populations in mothers (TT versus CC: OR = 3.595, 1.596, and 2.022, respectively). Many factors may contribute to the finding that the same polymorphism affects different ethnic populations to a different extent. First, the frequency of the T-allele varies in different ethnicities with different genetic backgrounds [@pone.0041689-Rady1]. Second, different populations may have different dietary patterns, such as intake of folic acid, vitamin B~12~, and vitamin B~6~, some of which may affect NTD development. Finally, analysis of the data from the various ethnic groups might eliminate some bias caused by language because only papers written in English or Chinese were included. Thus, large-scale studies should be performed to validate ethnic differences in the effect of this functional polymorphism on NTD risk.

When stratified by study design, significantly increased risks were also found in both population-based and hospital-based studies. Nevertheless, population-based studies have a higher risk than hospital-based studies. Hospital-based studies usually have a high risk of producing unreliable results because hospital-based controls may not always accurately represent the general population, especially when the genotypes under investigation are expected to affect disease conditions that might be observed in the hospital-based controls [@pone.0041689-Han1]. Thus, in genetic association studies, the selection of controls and matching status should be carefully considered. To reduce the bias, well-designed, population-based studies should be performed to explore the association.

Because heterogeneity is a potential problem when interpreting the results of all meta-analyses, we detected the source of heterogeneity by ethnicity, publication year, control source, and sample size and found that none substantially contributed to the heterogeneity. One possible reason might be the matching status.

It is assumed that *MTHFR* genetic polymorphisms play an important role in the development of NTDs; however, only 13% of NTDs were attributed to the *MTHFR C677T* mutation [@pone.0041689-Boduroglu1], suggesting that the *MTHFR C677T* polymorphism alone cannot be responsible for NTDs. Thus, potential gene-gene, maternal-foetal, genetic-nutritional interactions [@pone.0041689-Botto1], and other SNPs in the *MTHFR* gene may have an association with NTD risk.

 {#s4a}

### 1) Gene-gene interactions {#s4a1}

Folate metabolism is complex and involves several regulatory mechanisms. Genetic variations affecting protein function at any step may alter the balance of metabolites, and gene-gene interactions [@pone.0041689-Robien1]. The combination of *MTHFR* and cystathione-β-synthase (CBS) mutations was reported to have a fivefold increase in the risk for spina bifida compared with each variant alone [@pone.0041689-Botto2], indicating the presence of gene-gene interactions.

### 2) Maternal-foetal interactions {#s4a2}

Maternal variant genotypes were associated with NTD risk, indicating possible maternal-foetal interactions. Using family-based approaches, researchers have found that the OR increased to 4.1 (95% CI: 1.5, 11.1) if the mother had a TT genotype and her child a CT genotype and to 6.1 (95% CI: 1.0, 35.5) if both the mother and her child had TT genotypes [@pone.0041689-vanderPut4].

### 3) Genetic-nutritional interactions {#s4a3}

The combination of *MTHFR* mutations and low folate concentrations could lead to a hypomethylation of homocysteine to methionine, enhancing the impairment of folate metabolism and increasing the risk for NTDs [@pone.0041689-vanderPut1], suggesting a strong genetic-nutritional interaction. This interaction was found in a previous study that showed the combination of *MTHFR* TT genotype and RBC folate level in the lowest quartile conferred an odds ratio of 13.43 (95% CI: 2.49, 72.33) for an NTD case and an odds ratio of 3.28 (95% CI: 0.84, 12.85) for having offspring with NTDs [@pone.0041689-Christensen1].

Although these studies were hampered by small sample sizes, they illustrate the existence of potential interactions. Thus, further large-scale studies focusing on these complex interactions with NTD risk should be performed.

### 4) Other SNPs in the *MTHFR* gene {#s4a4}

Some researchers have demonstrated that other SNPs in *MTHFR* gene showed increased NTD risks, such as *A1298C* [@pone.0041689-DeMarco1], [@pone.0041689-vanderPut5], *C116T* [@pone.0041689-OLeary1], *G1793A* [@pone.0041689-OLeary1], and were linkage disequilibrium with *C677T* polymorphism. All these suggest these SNPs can be additional genetic factors for NTDs.

Limitations {#s4b}
-----------

Several potential limitations of this meta-analysis should be discussed. 1) Although the funnel plot and Egger\'s test showed no publication bias, selection bias may have occurred because only studies in English or Chinese were selected. 2) Our results were based on unadjusted estimates due to the absence of available information, such as supplementation of folic acid, maternal use of drugs, and other factors that are associated with NTD risk. 3) We did not consider the foetal *MTHFR C677T* polymorphisms due to the limited data. Despite the limitations listed above, our meta-analysis has some clear advantages. 1) The well-designed search and selection method significantly increased the statistical power of this meta-analysis. 2) No publication bias was detected, indicating that our pooled results are likely to be reliable.

In conclusion, our meta-analysis provided evidence that the *MTHFR C677T* polymorphism is a genetic risk factor for NTDs. Because NTDs are the most common congenital malformations worldwide and have a multifactorial aetiology, various genetic and environmental factors as well as their complex interactions implicated in the pathogenesis should be taken into account. Further functional studies to investigate folate-related gene polymorphisms, periconceptional multivitamin supplements, complex interactions and their role in development of NTDs are warranted.
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